Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622471 | 0.84 | SLC17A5 (0.64) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL5276812 | 0.84 | SLC17A5 (0.64) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL5622852 | 0.84 | SLC17A5 (0.64) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL5622971 | 0.83 | MEN1 (0.60) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9826754 | 0.77 | ALDH1A1 (0.56) | ALDH1A1POLBNPC1RAB9A | |
| SCHEMBL9716776 | 0.77 | ATM (0.67) | KMT2AALDH1A1 | |
| SCHEMBL7044299 | 0.77 | ATM (0.67) | KMT2AALDH1A1 | |
| SCHEMBL7044293 | 0.77 | ATM (0.67) | KMT2AALDH1A1 | |
| SCHEMBL7039089 | 0.77 | ATM (0.67) | KMT2AALDH1A1 | |
| SCHEMBL9716778 | 0.77 | ATM (0.67) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | claimed |
| EP-1559712-A1 | A method for manufacturing optically active coumaryl amino acid salts and the coumaryl aminoacid salts thus obtained | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-03 | — | — | EP | claimed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
| EP-1711483-A2 | A METHOD FOR MANUFACTURING OPTICALLY PURE COUMARYL AMINO ACID SALTS AND THE COUMARYL AMINO ACID SALTS THUS OBTAINED | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075448-A2 | A METHOD FOR MANUFACTURING OPTICALLY PURE COUMARYL AMINO ACIDS SALTS AND THE COUMARYL AMINO ACID SALTS THUS OBTAINED | INSTITUT NATIONAL DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-18 | — | — | WO | disclosed |
| EP-1559712-A1 | A method for manufacturing optically active coumaryl amino acid salts and the coumaryl aminoacid salts thus obtained | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | CRYAA, BCAT2, BCAT1 | MEN1 4557/4885KMT2A 3259/4885KDM4E 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.